Earlier, on December 12, Hawkins (NASDAQ:HWKN) acquired 40,000 restricted stock units, which will vest in full on December 12, 2025, contingent upon his continued service with the company. However, the acquisition of these units did not involve any monetary transaction as they were granted as part of his compensation. The company maintains a Fair overall financial health score according to InvestingPro's comprehensive analysis, which includes detailed metrics and valuation insights available in the Pro Research Report. The company maintains a Fair overall financial health score according to InvestingPro's comprehensive analysis, which includes detailed metrics and valuation insights available in the Pro Research Report. Earlier, on December 12, Hawkins acquired 40,000 restricted stock units, which will vest in full on December 12, 2025, contingent upon his continued service with the company. However, the acquisition of these units did not involve any monetary transaction as they were granted as part of his compensation. The company maintains a Fair overall financial health score according to InvestingPro's comprehensive analysis, which includes detailed metrics and valuation insights available in the Pro Research Report.
Earlier, on December 12, Hawkins acquired 40,000 restricted stock units, which will vest in full on December 12, 2025, contingent upon his continued service with the company. However, the acquisition of these units did not involve any monetary transaction as they were granted as part of his compensation.
In other recent news, Savara (NASDAQ:SVRA) Inc. reported earnings per share at ($0.12), slightly below the ($0.10) forecasted by Oppenheimer and consensus estimates. Despite this, analyst firms Piper Sandler, H.C. Wainwright, and Oppenheimer maintained their positive ratings on Savara. The company also announced a $100 million stock offering of 26,246,720 shares managed by firms such as Jefferies, Piper Sandler, and Guggenheim Securities.
H.C. Wainwright recently lowered its price target for Savara from $10 to $6 amid concerns over the company's ability to meet patient identification goals for Molbreevi, while Evercore ISI downgraded the stock from Outperform to In Line and reduced the price target to $5. Despite these changes, both firms maintained their buy ratings on Savara.
In other developments, Savara launched an Expanded Access Program for molgramostim, a potential treatment for autoimmune Pulmonary Alveolar Proteinosis (aPAP). The company also appointed Braden Parker as the new Chief Commercial Officer, bringing over 25 years of experience in the healthcare and biotech industry. These are some of the recent developments in the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.